KUALA LUMPUR, March 16 (Bernama) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announced Monica Gostissa, PhD, has joined its Scientific Advisory Board (SAB).
According to a statement, she joins existing board members: Frank Sistare, PhD; Andrew Goodman, PhD; David Hill, PhD; and Robert Rosenthal, PhD.
The SAB collaborates with Taconic management, providing scientific insight and guidance to expand the company’s product and service portfolio.
Taconic Biosciences chief executive officer, Nancy J. Sandy said: “We welcome Dr Gostissa to our team. She will provide valuable expertise and direction as Taconic continues developing the best animal model solutions to inform human clinical outcomes.”
Dr Gostissa's extensive career in the immunology and immuno-oncology fields brings new expertise to the board and complements Taconic’s leadership in these research areas.
The SAB members’ expertise in microbiome, oncology, neurobiology, and toxicology spaces mirror Taconic’s focus on innovation in these research areas.
Dr Gostissa is the Senior Director of In vivo and Ex vivo Sciences at Jounce Therapeutics, where she leads a multidisciplinary team with capabilities spanning in vivo pharmacology, ex-vivo 3D model development, and histopathology.
During her 20-year career in basic research, Dr Gostissa obtained extensive expertise in developing and interrogating complex mouse models of hematological and solid malignancies.
She obtained her PhD in molecular genetics from the International School for Advanced Studies in Trieste, Italy, and completed post-doctoral studies at Boston Children’s Hospital/Harvard Medical School.
-- BERNAMA
No comments:
Post a Comment